Share-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2013

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2013 is as follows:

	Number of shares		Weighted average exercise price
Options outstanding at June 30, 2013		14,434,970	$	21.75
Options granted		3,304,553		26.48
Less:
Options exercised		310,866		14.23
Options canceled or expired		354,729		24.33
Options outstanding at December 31, 2013		17,073,928	$	22.75

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Comprehensive Income

Share-based compensation expense recognized and included in the condensed consolidated statements of income was allocated as follows:

	Three months ended December 31,				Six months ended December 31,
(In thousands)	2013		2012		2013		2012
Cost of molecular diagnostic testing	$	209	$	271	$	432	$	560
Cost of companion diagnostic services		74		47		137		104
Research and development expense		846		869		1,627		1,678
Selling, general, and administrative expense		5,728		5,918		11,596		11,362
Total share-based compensation expense	$	6,857	$	7,105	$	13,792	$	13,704